Christina Mary MARIASELVAM

Dr. Christina Mary MARIASELVAM


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 December 2023 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
VKVallayyachari Kommoju
Vallayyachari Kommoju
CMChristina Mary MARIASELVAM
Christina Mary MARIASELVAM
SBSree Nethra Bulusu
Sree Nethra Bulusu
CKChengappa Kavadichanda
Chengappa Kavadichanda
PNPrakash Babu Narasimhan
Prakash Babu Narasimhan
VNVir Singh Negi
Vir Singh Negi


24 March 2025 in Rheumatology
Verified
Journal Article
Closed access
AGAishwarya Gopal
Aishwarya Gopal
CKChengappa Kavadichanda
Chengappa Kavadichanda
CMChristina Mary MARIASELVAM
Christina Mary MARIASELVAM
KHK T Harichandrakumar
K T Harichandrakumar
MTMolly Mary Thabah
Molly Mary Thabah
VNVir Singh Negi
Vir Singh Negi
Objectives: This study aimed to test whether immunosuppressant (IS) withdrawal is noninferior to glucocorticoid (GC) withdrawal in patients with SLE in remission. Methods: In this open-label, single-centre, randomized (1:1) controlled trial, we compared flare occurrence in stable SLE patients undergoing GC or IS tapering. Patients aged >18, on stable GC (prednisolone ≤7.5 mg/day) and maintenance non-biological IS for ≥3 years, in clinical remission for ≥1 year, were enrolled and assigned to taper GC or IS over 3 months. The primary endpoint was the proportion of patients experiencing a flare, defined by the SELENA-SLEDAI Flare Index (SFI) at 52 weeks. Patients in remission beyond 52 weeks were followed up to the maximum available follow-up duration beyond 104 weeks. Results: Between May and December 2021, 121 patients were randomized, and 117 (GC withdrawal, n = 58; IS withdrawal, n = 59) were included in the primary analysis. Flare occurred in 31% of the GC withdrawal group and 20.3% in the IS withdrawal group (risk difference, –10.6% [95% CI, −26.5 to 5.1]; P = 0.18), demonstrating the noninferiority of IS withdrawal. At maximum follow-up, 44.8% in the GC withdrawal group and 32.2% in the IS withdrawal group experienced a flare (risk difference, −12.6% [95% CI, −30.1 to 4.9]; P = 0.11), confirming the noninferiority of IS withdrawal at 2 years. Damage accrual was similar between the two groups at both endpoints. Conclusion: IS withdrawal is noninferior to GC withdrawal in SLE patients in long-term clinical remission. Personalized tapering strategies based on baseline damage and steroid exposure may optimize outcomes. Trial registration: The trial was registered with https://ctri.nic.in/, CTRI/2020/07/026712.

10 April 2024 in Immunologic Research
Verified
Journal Article
Closed access
PDF file
CMChristina Mary MARIASELVAM
Christina Mary MARIASELVAM
GSGaurav Seth
Gaurav Seth
CKChengappa Kavadichanda
Chengappa Kavadichanda
WBWahid Boukouaci
Wahid Boukouaci
CWChing-Lien Wu
Ching-Lien Wu
RTRyad Tamouza
Ryad Tamouza

21 November 2023 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AGAishwarya Gopal
Aishwarya Gopal
CKChengappa Kavadichanda
Chengappa Kavadichanda
MGMohan Sreelekha Gayathri
Mohan Sreelekha Gayathri
MGMamatha Gorijavolu
Mamatha Gorijavolu
DBDevender Bairwa
Devender Bairwa
VNVir Singh Negi
Vir Singh Negi

20 July 2024 in Lupus
Verified
Journal Article
Closed access
SBSree Nethra Bulusu
Sree Nethra Bulusu
CMChristina Mary MARIASELVAM
Christina Mary MARIASELVAM
SSSanket Shah
Sanket Shah
VKVallayyachari Kommoju
Vallayyachari Kommoju
CKChengappa Kavadichanda
Chengappa Kavadichanda
VNVir Singh Negi
Vir Singh Negi
Objectives: To assess the longitudinal effect of cyclophosphamide (CYC) treatment on type-I interferon (IFN) signature in proliferative lupus nephritis (LN) and its role in predicting treatment response. Methods: Fifty-four biopsy proven proliferative LN patients scheduled to receive high-dose (HD) or low-dose (LD) CYC were recruited and followed up for six months. At six months, patients were classified as clinical responders (CR) or non-responders (NR) to treatment, using the EULAR/EDTA criteria. An IFN-gene based score (IGS) was developed from the mean log-transformed gene expression of MX1, OAS1, IFIT1, OASL, IFIT4, LY6E, IRF7 at baseline, three and six months. Longitudinal changes of IGS within and between groups were assessed and ΔIGS, which is the difference in IGS between baseline and three months was calculated. Independent predictors of non-response were identified and an ROC analysis was performed to evaluate their utility to predict NR. Results: There was a dynamic change in IGS within the HD, LD, CR, and NR groups. Compared to baseline, there was a significant decrease in IGS at three months in HD and LD groups (HD group: 2.01 to 1.14, p = .001; LD group = 2.01 to 0.81, p < .001), followed by a significant increase from three to six months in LD group (LD: 0.81 to 1.51, p = .03; HD: 1.14 to 1.54, p = .300). A decrease in IGS from baseline to three months was seen in both CR (2.13 to 0.79, p < .001) and NR groups (1.83 to 1.27, p = .046), and a significant increase from three to six months was observed only in the CR group (CR: 0.79 to 1.57, p = .006; NR: 1.27 to 1.46, p = 1). ΔIGS (baseline to three months) was higher in CR compared to NR group (−1.339 vs −0.563, p = .017). ROC analysis showed that the model comprising of 0.81 fold decrease in IGS from baseline to three months, endocapillary hypercellularity and interstitial inflammation on renal histopathology predicted non-response with a sensitivity of 83.3% and specificity of 71.4%. Conclusion: In proliferative LN, treated with HD or LD-CYC, combined model comprising of decrease in IGS score by 0.81 fold from baseline to three months, along with important histopathological features such as endocapillary hypercellularity and interstitial inflammation had better predictive capability for non-response.